SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss

Swedish Orphan Biovitrum (STO: SOBI) says that it has entered into a distribution agreement with privately-held PharmaSwiss to market four products approved for the treatment of indications within the oncology, cardiovascular and anti-infective therapy areas. Financial terms of the deal were not disclosed.

The products in question are: Megace (megestrol), a progestogen hormone drug is indicated for the treatment of certain hormone-dependent neoplasms such as breast cancer; Monopril (fosinopril), an angiotensin converting enzyme (ACE) inhibitor indicated for treatment of hypertension and congestive heart failure; Cefzil (cefprozil), a broad-spectrum cephalosporin antibiotic indicated for the treatment of mild to moderate infections; and Duricef (cefadroxil), a cephalosporin antibiotic indicated for the treatment of urinary tract infections, skin infections, pharyngitis and/or tonsillitis, where the infections are caused by susceptible strains of designated microorganisms.

Under the terms of the accord, SOBI will have distribution rights in Ireland, the UK, France, Italy, Germany, Spain, Finland, Sweden, Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal and Luxembourg. All products are approved within the SOBI territory, where sales in 2012 were around 120 million Swedish kronor ($18.7 million). SOBI says it expects to initiate distribution for the portfolio by the end of the first quarter of 2013.